Pre-made Caplacizumab biosimilar ( Nanobody, anti-VWF therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-093
Anti-VWF therapeutic antibody (Pre-made Caplacizumab biosimilar,Nanobody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-VWF therapeutic antibody (Pre-made Caplacizumab biosimilar,Nanobody)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Approved||Thrombotic thrombocytopenic purpura|
|Development Tech||Nanobody Technology|